Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study

Sayaka Uda, Tadaaki Yamada, Akihiro Yoshimura, Yasuhiro Goto, Kohei Yoshimine, Yoichi Nakamura, Shinsuke Shiotsu, Takashi Yokoi, Nobuyo Tamiya, Hideharu Kimura, Yusuke Chihara, Yukihiro Umeda, Miiru Izumi, Takayuki Takeda, Takahiro Yamada, Makoto Hibino, Osamu Hiranuma, Kazuhiro Ito, Asuka Okada, Shuji OsugiYoshizumi Takemura, Hiroshi Ishii, Kenji Chibana, Isao Hasegawa, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors. Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method. Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034). Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.

Original languageEnglish
Pages (from-to)1847-1857
Number of pages11
JournalTranslational Lung Cancer Research
Volume11
Issue number9
DOIs
Publication statusPublished - 09-2022

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint

Dive into the research topics of 'Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study'. Together they form a unique fingerprint.

Cite this